

## **Clarification regarding news on Almirall receiving an offer for acquiring a package of Almirall shares**

**Barcelona, 2 September 2008.-** Regarding the news that have appeared early this morning on Almirall indicating a potential offer on Almirall stock on behalf of a Dutch fund, the company wants to indicate that it has not received -neither formally nor informally- an offer nor and indication for acquiring a package of Almirall shares. The company is not aware either of actions intended to acquire a significant package of the Almirall stock.

### **About Almirall**

Almirall, an international pharmaceutical company based on innovation and committed to health, headquartered in Barcelona, Spain, researches, develops, manufactures and commercialises its own R&D and licensed drugs with the aim of improving people's health and wellbeing.

The therapeutic areas on which Almirall focuses its research resources are related to the treatment of asthma, COPD (Chronic Obstructive Pulmonary Disease), rheumatoid arthritis, multiple sclerosis, psoriasis and dermatology in general.

Almirall is currently present in over 70 countries with direct presence in Europe and Latin America through 11 affiliates.

For further information please visit the website at: [www.almirall.com](http://www.almirall.com)

#### **More information:**

Ketchum SEIS

Patricia Mansilla

34 91 788 32 00

[patricia.mansilla@ketchum.com](mailto:patricia.mansilla@ketchum.com)